Salmeterol Xinafoate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA. It is grouped under the following drug class(es): Beta-2 agonists and Bronchodilators. Its therapeutic use is listed as anti-asthmatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Serevent diskus, Asmerole, Dilamax, Inaspir and Ultrabeta. Its PubChem CID is 56801.
Salmeterol xinafoate
| CAS No | 94749-08-3 |
|---|---|
| Molecular Formula | C36H45NO7 |
| Molecular Weight | 603.7 g/mol |
| Synonyms | 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Salmeterol Xinafoate is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 2 investigational indications.
The listed CAS number is 94749-08-3.
The listed molecular formula is C36H45NO7.
The listed molecular weight is 603.7 g/mol.
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol;1-hydroxynaphthalene-2-carboxylic acid.
The source lists Serevent diskus, Asmerole, Dilamax, Inaspir and Ultrabeta.